North America Flow Cytometry Market

North America Flow Cytometry Market Size (2023 to 2028)

The Flow Cytometry Market size in North America has been estimated at USD 1707.86 Million in 2023 and will be worth USD 2751.68 Million by 2028 at a CAGR of 10.1% during the forecast period. In North America, the United States is dominating the market.

The North America Flow Cytometry Market is primarily stimulated by technological progress and high adoption in various research and diagnostic applications. Besides, the increasing incidence rates of diseases such as cancer and HIV are expected to stimulate flow cytometric technology in diagnostic applications. The rising economy in developed countries like the U.S and others is likely to fuel the growth rate of the market. The rise in the elderly population is enhancing the growth rate of the market. 

However, the shortage of skilled technicians in monitoring the systems is slowly restraining the market demand. Also, government bodies' stringent rules and regulations for approvals inhibit the growth rate of the North America Flow Cytometry Market. 

This research report on the North America Flow Cytometry Market has been segmented and sub-segmented into the following categories:

By Technology: 

• Cell-based
• Bead-based

By Product: 

• Reagents & Consumables
• Flow Cytometry Instruments

By Application: 

• Research
• Clinical
• Industrial

By End-users: 

• Commercial Organizations
• Research Institutes
• Clinical Testing Labs

By Country: 

• The U.S.
• Canada
• Rest of North America

Regionally, North America is the biggest market in terms of market share globally, followed by Europe. The market in North America is majorly driven due to factors such as increasing application of flow cytometry techniques in cancer research, increasing adoption of low cost and compact flow cytometers in clinical diagnostics and research laboratories, and growing infrastructure quality laboratory and clinical research.

The flow cytometry market in North America was dominating the global market. It accounted for a market share of 39.8% in 2019 due to the favorable government reforms for developing advanced technologies in molecular diagnostics, growing awareness among the people, and availability of expert professionals. Also, increasing full applications relevant for flow cytometry methods for different cancer research activities and increasing obtainment of low cost accelerates this region's growth. The growth is also due to the increase in the enlargement of new products, which produces opportunities in the analysis period.

The U.S. flow cytometry market is expected to account for the largest market share in the North American market. The high occurrence rate of various cancers such as breast cancer, lung cancer, prostate cancer, colon and rectum, skin and bladder cancer, and other chronic diseases is majorly attributing the market growth in the United States. The existence of many clinical research labs and many pharmaceutical industries boost up the development of this region. In this country, the growing number of cancer cases, which in turn creates more demand for the flow cytometry market in this region.

The Canadian flow cytometry market is predicted to be held as the second-largest share in the flow cytometry market during the analysis period as there are high research and development activities in this country, the growing occurrence rate of cancer and HIV. The Canadian market is expected to have a colossal healthcare industry; key players concentrate more on inventing and launching new products and devices into the market, fueling the growth.

Companies playing a dominant role in the North America Flow Cytometry Market profiled in this report are Becton, Dickinson and Company, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Merck KGaA, Sysmex Partec GmbH, Luminex Corporation, Miltenyi Biotec GmbH, Bio-Rad Laboratories, Inc., Sony Biotechnology, Life Technologies Corporation Inc., EMD Millipore Corporation, Miltenyi Biotec, Thermo Fischer Scientific, Agilent Technologies, Inc. and Affymetix Inc.

In September 2017, Beckman Coulter, Inc. (United States) released its first CytoFLEX LX flow cytometry for cancer researchers, which has the visible spectrum in a standard configuration. This launch allowed the development of its activity in flow cytometry.